EZZ Life Science Holdings Limited (ASX:EZZ)
Australia · Delayed Price · Currency is AUD 0.4100
-0.0050 (-1.20%)
Sep 18, 2026, 11:52 AM AEST
EZZ Life Science Holdings Revenue
In the fiscal year ending June 30, 2026, EZZ Life Science Holdings had annual revenue of 46.28M AUD, down -30.79%. EZZ Life Science Holdings had revenue of 24.82M in the half year ending December 31, 2025, with 14.38% growth.
Revenue
46.28M
Revenue Growth
-36.39%
P/S Ratio
0.42
Revenue / Employee
n/a
Employees
n/a
Market Cap
19.53M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2026 | 46.28M | -20.59M | -30.79% |
| Jun 30, 2025 | 66.87M | 430.32K | 0.65% |
| Jun 30, 2024 | 66.44M | 29.30M | 78.88% |
| Jun 30, 2023 | 37.14M | 22.12M | 147.26% |
| Jun 30, 2022 | 15.02M | -7.27M | -32.60% |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Immuron | 7.71M |
| Argenica Therapeutics | 5.48M |
| Neurotech International | 4.73M |
| Proteomics International Laboratories | 3.37M |
| Imugene | 2.09M |
| Noxopharm | 1.43M |
| Cambium Bio | 1.23M |
| NeuroScientific Biopharmaceuticals | 402.66K |